Cayman Pharma s.r.o

Exhibitor at CPHI Frankfurt 2022 stand 120A23, API
About Us

Cayman Pharma is the world's most reliable source of prostaglandin Active Pharmaceutical Ingredients (APIs) using its own patented route to manufacture APIs for erectile dysfunction, ophthalmic, veterinary, and vascular applications. Cayman Pharma has an excellent track record with over 30 years of experience and an outstanding record of regulatory compliance. Cayman Pharma was formed in October of 2006 by the merger of two companies with very different geographic origins. Both, however, had unparalleled experience and expertise in Prostaglandin Chemistry. One was Cayman Chemical, a research biochemical company with global recognition as an expert in the field of lipid chemistry. The other was NeraPharm, a company located within the Spolana complex north of Prague since the late 1970s, but only operating as an independent legal entity since 2002. NeraPharm was conceived during the era of Soviet economic domination and central planning. Their goal, which was largely achieved, was to implement independent production of important veterinary prostaglandins for the entire Eastern Bloc. Cayman had its beginnings just a few years later, in 1980. Cayman's vision, also largely accomplished, was to demonstrate that naturally occurring prostaglandins from corals could be an economical and versatile raw material. Targeting the research community instead of the human and veterinary market, Cayman was soon selling a wide variety of extremely pure and valuable prostaglandin standards. Cayman Pharma represents the joining of almost 60 years of experience with prostaglandin synthesis and biochemistry. NeraPharm brings to the new company a deep understanding of GMP manufacturing under US FDA and EMEA standards, and many years of experience supplying pharmaceutical grade active ingredients. The Czech company also provides Cayman with a tremendous boost in manufacturing capacity. Cayman, on the other hand, brings cutting edge knowledge both in the research field and in GMP methods for the most advanced prostaglandin compounds. Drug candidates for newer indications such as glaucoma, male and female sexual dysfunction, and pulmonary hypertension are all part of the Cayman portfolio. Cayman Pharma will strive to make the best possible use of its joint EU and US GMP manufacturing operations to ensure that the prostaglandin API that the customer needs is properly certified and ready for release.

  • CZ
  • 2015
    On CPHI since
Company types
Contact info
Event information
CPHI Frankfurt 2022
  • 1-3 November 2022
  • Messe Frankfurt, Germany
  • Visit us at stand 120A23, API

Products Featured at CPHI Frankfurt 2022

  • CGMP (+)-Cloprostenol (sodium salt) 

    Product CGMP (+)-Cloprostenol (sodium salt) 

    (+)-Cloprostenol is the active enantiomer of Cloprostenol. Cloprostenol is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. The ASMF for (+)-Cloprostenol (sodium salt) is on file in several EU member states.
  • CGMP (±)-Cloprostenol (sodium salt) 

    Product CGMP (±)-Cloprostenol (sodium salt) 

    Cloprostenol is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. The VMF for (±)-Cloprostenol (sodium salt) is on file with the US FDA, Canada, Russia, and the ASMF for (±)-Cloprostenol (sodium salt) is o...
  • CGMP Alprostadil 

    Product CGMP Alprostadil 

    Alprostadil is a vasodilator, and finds clinical use in treating erectile dysfunction, in improving blood flow in peripheral vascular disease, and in maintaining coronary circulation in neonates with vascular anomalies. The DMF for Alprostadil is on file with the US FDA, Canada, India, in many EU member st...
  • CGMP Bimatoprost

    Product CGMP Bimatoprost

    Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. The DMF is on file with the US FDA, Canada, and in several EU member states.
  • CGMP Epoprostenol (sodium salt)

    Product CGMP Epoprostenol (sodium salt)

    Epoprostenol is a potent vasodilator and antiplatelet substance with a very short physiologic half-life. It is used for the treatment of pulmonary hypertension. The DMF for Epoprostenol Sodium Salt is on file with the US FDA, Canada, Japan, Australia, and several EU member states.